Company Overview
Radiopharm Theranostics Limited operates as a clinical-stage radiotherapeutics company focused on the research and development of radiopharmaceutical products designed for diagnostic and therapeutic applications in areas characterized by high unmet medical needs. The firm is positioned within the Healthcare sector and specifically within the Biotechnology industry, which implies a business model reliant on significant scientific innovation and regulatory approval processes before generating substantial commercial revenue. The company's current scale is defined by a market capitalization of $33.50M, annual revenue of $16.28M, and an employee base of 14 individuals. These valuation and revenue figures indicate that Radiopharm Theranostics is a micro-cap entity with a relatively small operational footprint, suggesting that its market position is currently supported more by intellectual property potential than by established commercial market dominance or diversified product lines.
Financial Health
The company reported a revenue of $16.28M over the trailing twelve months, yet it recorded a net income of $-46,582,476 and an EBITDA of $-39,179,988, revealing a cost structure where expenses significantly outweigh revenue generation. This substantial gap between revenue and net income highlights the heavy investment in research and development or other operating costs typical of early-stage biotechnology firms that have not yet achieved profitability. The free cash flow stands at $-20,874,536, indicating that the company is consuming cash reserves to fund its operations rather than generating surplus liquidity for distribution to shareholders or debt repayment. Analysis of the margin structure shows a gross margin of -136.5%, an operating margin of -423.8%, and a profit margin of -286.2%, all of which indicate severe operational inefficiencies relative to sales revenue and high fixed cost burdens relative to current output. In terms of liquidity and leverage, the company holds $34.52M in cash while the debt metric is listed as N/A, suggesting a balance sheet that relies on cash reserves to offset losses rather than traditional debt financing. The current ratio is 3.01, which indicates that the company possesses more than three times the current assets needed to cover its short-term liabilities, pointing to a conservative approach to managing immediate obligations despite the lack of earnings. Regarding return metrics, the return on equity is -92.1% and the return on assets is -28.3%, revealing that management has not yet been effective in generating positive returns on the capital invested in the business, a common characteristic of companies in the clinical-stage development phase.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of earnings, while the forward P/E is listed as -1.69, implying that the market is pricing in future earnings expectations that have not yet materialized or that the stock is priced based on non-earnings multiples at this time. The price-to-book ratio is 411.43, which indicates a substantial market premium over the company's book value, suggesting that investors are valuing the firm based on its potential future assets or intellectual property rather than its current net asset position. Alternative valuation metrics such as the price-to-sales ratio of 2.06 and an EV/EBITDA of -383.53 suggest that the stock is being valued relative to revenue and enterprise value, though the negative EV/EBITDA reflects the company's inability to generate earnings at this stage. The 52-week high is $16.25 and the 52-week low is $3.50, placing the current trading range within a wide band where the stock has experienced significant volatility over the past year. The beta value is 0.90, which means the stock's price volatility is roughly in line with the broader market, indicating that it does not exhibit extreme sensitivity to general market movements despite its small market cap.
Growth & Income
Radiopharm Theranostics Limited reported a revenue growth of 154.5% year over year, while earnings growth is listed as N/A due to the company's continued losses, implying that revenue expansion is occurring faster than earnings improvement because the bottom line has not yet turned positive. Since the company is not a dividend payer, there is no dividend yield or payout ratio to assess, meaning the company reinvests all available earnings and cash flow into growth initiatives such as clinical trials and product development rather than distributing income to shareholders. The overall growth and income profile is characterized by rapid top-line expansion coupled with a complete lack of current profitability and dividend distribution, typical of high-risk biotechnology ventures seeking to validate their clinical-stage products before commercialization.